Exciting Advances in AI-Driven Coronary Care
Heartflow, Inc., the leader in AI technology for coronary artery disease (CAD), is set to present groundbreaking data and innovations at the highly anticipated Society of Cardiovascular Computed Tomography (SCCT) Annual Scientific Meeting. This event will take place from July 17-20, 2025, and will mark a significant moment for clinicians managing CAD. Heartflow is focusing especially on its AI-enabled Plaque Analysis, which is changing the landscape of CAD management.
Influence of the DECIDE Registry
At the core of the discussion will be final primary endpoint data from the DECIDE Registry. This registry has shown that Heartflow's advanced Plaque Analysis tool can lead to important changes in medical management for over half of patients when compared to using coronary computed tomography angiography (CCTA) alone. Full clinical insights are set to be shared at the SCCT meeting, indicating just how impactful Heartflow's technology has been in improving patient outcomes.
Cian McCarthy: A Recognized Leader
The DECIDE Registry has gained recognition within the medical community and is spearheaded by investigator Cian McCarthy, MB, BCH, BAO, SM, who will receive the prestigious 2025 SCCT Clinical Trials and Registries Award. This award celebrates the innovative use of CCTA-based analyses in understanding atherosclerotic burdens within CAD diagnosis and treatment. The award presentation will occur at the SCCT 2025 meeting, accompanied by a showcase of the study's results.
The Largest Study of Its Kind
Remarkably, the DECIDE Registry is the largest prospective study in its domain, gathering real-world data across multiple sites to examine how Heartflow's AI-enabled Plaque Analysis can reshape medical management strategies. The ambitious study aims to enroll approximately 20,000 patients at over 30 locations throughout the United States, contributing to a deeper understanding of CAD.
Next Generation of Plaque Analysis
Heartflow is also thrilled to unveil its next-generation Plaque Analysis technology during the conference. This advancement is supported by a significantly expanded dataset of age- and sex-specific nomograms for assessing atherosclerotic plaque. The various presentations at SCCT, coupled with demonstrations of this enhanced technology, underline Heartflow's dedication to delivering clinical evidence and innovating in cardiovascular management.
Heartflow's Vision for the Future
As Heartflow celebrates 15 years of innovation alongside SCCT's 20th annual meeting, the commitment to transforming CAD diagnosis, treatment, and management remains unwavering. Chief Medical Officer Campbell Rogers, M.D., FACC, stated, "We are excited to share our next-generation AI-enabled Plaque Analysis along with our award-winning clinical research. Combining the DECIDE Registry with this enhanced technology equips clinicians with vital insights necessary for personalized patient treatment decisions."
Key Presentations at SCCT
Heartflow's presentations at the SCCT event will include:
- DECIDE Registry Primary Endpoint: Focusing on guiding preventive care strategies for patients with atherosclerotic plaque observed through CCTA.
- Expanded Plaque Nomogram: Detailed CT-derived nomograms illustrating coronary plaque volume based on age and sex.
- Cost Economics: Analyzing long-term outcomes and costs when integrating AI-enabled CCTA plaque analysis as compared to traditional care.
Join Heartflow at SCCT
Heartflow invites all attendees to participate in various engaging activities during the meeting, including an educational dinner, symposium, and interactive workshops, further fostering collaboration and knowledge sharing among cardiovascular professionals.
About Heartflow, Inc.
Heartflow is on a mission to revolutionize coronary care, effectively transforming CAD into a condition that is screenable, diagnosable, and manageable. The Heartflow One platform provides a comprehensive, non-invasive approach to precision coronary care, enabling clinicians to utilize patient insights throughout the CCTA pathway. Backed by extensive research and clinical support, Heartflow has been instrumental in assisting healthcare professionals in managing over 400,000 patients globally.
Frequently Asked Questions
What is the focus of Heartflow's presentation at SCCT 2025?
Heartflow will present new data on its AI-enabled Plaque Analysis and findings from the DECIDE Registry, showcasing its impact on CAD management.
Who is Cian McCarthy?
Cian McCarthy is the DECIDE Registry investigator recognized with the 2025 SCCT Clinical Trials and Registries Award for his work in CAD research.
What is the significance of the DECIDE Registry?
The DECIDE Registry is the largest prospective study that assesses how AI technology can enhance the management of CAD compared to standard imaging techniques.
What are some key topics Heartflow will cover at the meeting?
Heartflow will address the primary outcomes of the DECIDE Registry, expanded plaque nomograms, and cost economics for CAD treatment.
How does Heartflow aim to improve patient care?
Heartflow's technologies are designed to provide deeper insights for clinicians, helping them make more informed, personalized treatment decisions for their patients.
